CN112353850A - 用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法 - Google Patents
用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法 Download PDFInfo
- Publication number
- CN112353850A CN112353850A CN202011328982.9A CN202011328982A CN112353850A CN 112353850 A CN112353850 A CN 112353850A CN 202011328982 A CN202011328982 A CN 202011328982A CN 112353850 A CN112353850 A CN 112353850A
- Authority
- CN
- China
- Prior art keywords
- parts
- leaves
- fatty liver
- hyperlipidemia
- namely
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 47
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 47
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 47
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 46
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 40
- 235000005911 diet Nutrition 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000037213 diet Effects 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 16
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 16
- 235000004347 Perilla Nutrition 0.000 claims abstract description 16
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 16
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 16
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 15
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 15
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 15
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 15
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 15
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 15
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 15
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 14
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 14
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 14
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 14
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 12
- 241000219780 Pueraria Species 0.000 claims abstract description 7
- 244000124853 Perilla frutescens Species 0.000 claims abstract 7
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 7
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims description 16
- 241000723343 Cichorium Species 0.000 claims description 14
- 241000218236 Cannabis Species 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 230000000378 dietary effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 244000046146 Pueraria lobata Species 0.000 claims description 6
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 1
- 235000009120 camo Nutrition 0.000 claims 1
- 235000005607 chanvre indien Nutrition 0.000 claims 1
- 239000011487 hemp Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000009471 action Effects 0.000 abstract description 8
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 244000298479 Cichorium intybus Species 0.000 abstract 1
- 240000004308 marijuana Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 241000229722 Perilla <angiosperm> Species 0.000 description 9
- 241000219304 Portulacaceae Species 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 241000229143 Hippophae Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 235000008714 apigenin Nutrition 0.000 description 3
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 3
- 229940117893 apigenin Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- -1 cichoric acid lactone Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000008777 kaempferol Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004132 lipogenesis Effects 0.000 description 3
- 235000009498 luteolin Nutrition 0.000 description 3
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 3
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 2
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 102000019267 Hepatic lipases Human genes 0.000 description 2
- 108050006747 Hepatic lipases Proteins 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- VJQAFLAZRVKAKM-QQUHWDOBSA-N lactucin Chemical compound O[C@@H]1CC(C)=C2C(=O)C=C(CO)[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 VJQAFLAZRVKAKM-QQUHWDOBSA-N 0.000 description 2
- VJQAFLAZRVKAKM-UHFFFAOYSA-N lactucine Natural products OC1CC(C)=C2C(=O)C=C(CO)C2C2OC(=O)C(=C)C21 VJQAFLAZRVKAKM-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- QZMAEZWZCGBZFK-AOJWCAIYSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2s,3r Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QZMAEZWZCGBZFK-AOJWCAIYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QZMAEZWZCGBZFK-UHFFFAOYSA-N 28-(beta-D-Glucopyranosyloxy)-28-oxoolean-12-en-3beta-yl 3-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OC(CO)C(O)C(O)C1O QZMAEZWZCGBZFK-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- HFJDWELARBQGBQ-PFLZFKCOSA-N Cassiaside B2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC=1C=C(C=C2C=C3C(C(C=C(C)O3)=O)=C(O)C2=1)OC)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HFJDWELARBQGBQ-PFLZFKCOSA-N 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 241000488874 Sonchus Species 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 235000006193 cichoric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101150046266 foxo gene Proteins 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- KPJWZUAARPJYSB-UHFFFAOYSA-N glycoside C Natural products CC1(C)OC(=O)C23CCC1C2(O)CCC(C1(CCC24)C)(C)C3CCC1C2(C)CCCC4(C)COC(C(C(O)C1O)OC2C(C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O KPJWZUAARPJYSB-UHFFFAOYSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HFJDWELARBQGBQ-UHFFFAOYSA-N rubrofusarin tetraglucoside Natural products C=12C(O)=C(C(C=C(C)O3)=O)C3=CC2=CC(OC)=CC=1OC(C(C(O)C1O)O)OC1COC(C1O)OC(CO)C(O)C1OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O HFJDWELARBQGBQ-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 244000209700 shan ge teng Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000008886 xiangdan Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种用于高脂血和脂肪肝的药膳食疗产品组合物,由以下重量份的原料制备而成:沙棘叶1~15份,辣木叶1~20份,菊苣1~15份,余甘子1~20份,马齿苋1~20份,决明子1~20份,野葛根1~15份,紫苏子1~15份,火麻仁1~20份,昆布1~16份,荷叶1~15份,壳寡糖0.1~3份,低聚木糖0.5~5份。以及,提供上述用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法。所述用于高脂血和脂肪肝的药膳食疗产品组合物疗效明确、作用靶点和药理效应清晰、原料来源广、成本低、制备方法简单,患者依从性高等特点,可以有效防治高血脂和缓解其引起的相关症状。
Description
技术领域
本发明属于保健品技术领域,具体涉及一种用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法。
背景技术
脂肪肝(fatty liver)是指由于各种原因引起的肝细胞内脂肪堆积过多的病变。调查数据显示我国成年人脂肪肝的发病率在20%-30%,已取代慢性乙型肝炎成为我国最常见慢性肝病。脂肪肝与高脂血症是一对孪生兄弟。据近年抽样调查数据,高脂血症在健康体检人群中的患病率更是高达46.8%。
现代医学对脂肪肝和高脂血症现在尚缺乏理想的治疗方法,主要的化学药物有他汀类、贝特类、胆固醇吸收抑制类,单一药物常常疗效有限,而且存在不同程度肝肾毒性、肌肉酸痛、甚至横纹肌溶解等副作用。
中医药被认为对高血脂、脂肪肝的疗效明确,而且安全低毒。中成药主要有:丹田降脂丸、血脂康胶囊、香丹清脂颗粒,降脂灵片等等,但是这些都属于药物类产品,这些药品需要在临床医生或者药师的指导下用药,不宜用于预防,不属于食同源类健康产品,且目前相关产品的成分不清楚、作用靶点不清楚。现代药理研究显示有大量药食同源的中药也具有良好降脂作用。为了充分发挥传统中医药的防治优势,开发系列早期预防、中期治疗、后期康复的安全有效的、质量可靠、有效成分清晰、作用靶点清楚的精准药膳,具有非常重要的意义和较大市场需求。
发明内容
本发明所要解决的技术问题在于克服现有技术之缺陷,提供一种用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法。
本发明提供一种用于高脂血和脂肪肝的药膳食疗产品组合物,由以下重量份的原料制备而成:
沙棘叶1~15份,
辣木叶1~20份,
菊苣1~15份,
余甘子1~20份,
马齿苋1~20份,
决明子1~20份,
野葛根1~15份,
紫苏子1~15份,
火麻仁1~20份,
昆布1~16份,
荷叶1~15份,
壳寡糖0.1~3份,
低聚木糖0.5~5份。
以及,一种用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法,其包括如下步骤:
按照上述用于高脂血和脂肪肝的药膳食疗产品组合物的重量份称取原料,将沙棘叶,辣木叶,菊苣,余甘子,马齿苋,决明子,野葛根,紫苏子,火麻仁,昆布和荷叶混合,加8~15倍质量份的水浸泡15~60分钟,加热回流提取0.5~2小时,80~200目过滤,得第一提取液;
向药渣中加8~15倍质量份的水回流提取0.5~2小时,80~200目过滤,得第二提取液;
将第一提取液和第二提取液混合,浓缩,加入壳寡糖和低聚木糖,获得所述用于高脂血和脂肪肝的药膳食疗产品组合物。
本发明的用于高脂血和脂肪肝的药膳食疗产品组合物,蠲浊化湿、降脂护肝,防治高脂血症和脂肪肝。其具有显著的降血脂活性,降低总胆固醇、甘油三酯和低密度脂蛋白;抗炎、抗氧化、保护肝脏;提高总脂酶活性,加速脂肪降解;改善胰岛素抵抗,减少脂肪生成;改善肠道微生态,减少脂肪吸收。网络药理分析发现本品中很多成分可以有效的防治高血脂和缓解其引起的相关症状,是一款主成分清晰,靶点明确的精准药膳产品。进一步,所述用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法采用特定的工艺制备,效果好,成本低,符合产业化生产需要。
附图说明
图1是本发明实施例提供的用于高脂血和脂肪肝的药膳食疗产品组合物的中药原料-活性成分-作用靶点关联网络图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明实施例提供一种用于高脂血和脂肪肝的药膳食疗产品组合物,由以下重量份的原料制备而成:
沙棘叶1~15份,
辣木叶1~20份,
菊苣1~15份,
余甘子1~20份,
马齿苋1~20份,
决明子1~20份,
野葛根1~15份,
紫苏子1~15份,
火麻仁1~20份,
昆布1~16份,
荷叶1~15份,
壳寡糖0.1~3份,
低聚木糖0.5~5份。
其中,上述原料中的大黄素甲醚、大黄酚、山莴苣苦素、菊苣内酯A、苦苣菜苷C等具有明显的抗炎活性。菊苣减少血清中TC、TG、LDL、AST、ALT水平,抑制IL-6、TNF-α、FFA、IKKβ、NF-κB p65表达,改善糖尿病-脂肪肝大鼠的肝细胞肿胀、坏死,抑制肝细胞中脂肪聚集。Lactucin通过抑制JAK2/STAT3磷酸化减少脂肪生成相关的基因表达,减少肥胖,保护肝脏。菊苣中的黄酮类化合物,比如Kaempferol、Luteolin具有抗氧化、抗炎作用,能保护肝脏。决明子中的蒽醌类化合物能抑制脂肪肝大鼠的脂肪过氧化,降低血清TC、TG、LDL、AST、ALT水平,保护肝脏,也能改善糖脂代谢。其中大黄素emodin减少血清TC、TG、LDL、AST、ALT水平,下调CYP2E1,增加PPARγ等基因表达,改善酒精性肝损伤和高脂血症。Chrysophanol降低血糖水平,减少血中TC、TG并增加HDL-C水平,抑制肥胖,同时减少IL1β、IL6,增加IL10,抑制炎症,这些作用于激活AMPK/SIRT1通路有关。Chrysophanol和Emodin通过降低gamma-glutamyl transpeptidase(GGT)活性,升高GSH水平,增加CYP2E1表达抑制酒精性肝损伤,对脂肪肝和高脂血症有一定预防作用。Cassiaside B2抑制蛋白酪氨酸磷酸酶1B(PTP1B),改善胰岛素抵抗,降低血糖;也能通过抑制5-HT2C减少饮食摄入,发挥抗肥胖作用。昆布多糖能增强LCAT、PL、LPL活性,降低血清TC、TG、LDL水平,减轻体重并改善高脂血症。Fucoidan减少糖尿病小鼠肝组织中FBG、TC、TG、AST、ALT、MDA水平以及增加血清中SOD、CAT、胰岛素水平,改善糖尿病引起的肝损伤。余甘子具有很好的抗高脂血症、抗动脉硬化、抗糖尿作用,其中的山奈酚和木犀草素可抑制DPP4活性发挥抗糖尿病作用。没食子酸减少脂质过氧化,降低AST、ALT水平,抑制TNFα和IL8,通过抗氧化发挥肝保护作用。EGCG不仅能明显降低体重,肠系膜脂肪量,空腹血糖,胰岛素抵抗,血清胆固醇和脂肪肝的严重程度;EGCG增加胆固醇7α-羟化酶,HMG-CoA还原酶,LDL水平,降低肠道胆汁酸含量;还能通过TGF/SMAD,PI3 K/Akt/FoxO1,NFκB等信号通路发挥抗氧化抗炎作用,从而减轻脂肪肝。Myricetin减少血糖、血清胆固醇、甘油三酯水平,降低血压;也有抗心律失常、保护心肌缺血作用,它能减慢异丙肾上腺素诱导的心律加快、减少血清LDH、CK、AST、ALT水平、升高SOD、CAT水平。Nuciferine减少饮食摄入、体重,降低血清TC、TG、LDL-C、FFA水平,抑制TNFα、IL6等炎症因子释放,增加SOD、CAT、GPx等抗氧化酶,改善胰岛素抵抗,调节脂肪生成的相关基因表达,最终改善高脂诱导的肝脏损伤变性和代谢综合征。紫苏子中含有亚油酸、α-亚麻酸等不饱和脂肪酸,亚油酸、α-亚麻酸能降低血浆中TC、TG水平,增加血清脂联素,改善胰岛素抵抗,减轻肝脏肿大,抑制TNFα表达。葛根素通过抗氧化作用保护肝脏,抑制脂质过氧化,减少血清中TC、TG、LDL-C,增加HDL-C,其降血脂作用与调节CYP7A1、HMG-CoA-R、LDLR有关。大豆苷元通过促进脂肪细胞分化,激活PPARγ来增加GLUT4和IRS-1表达,从而提高胰岛素刺激的脂肪细胞中葡萄糖摄取,发挥抗糖尿作用。马齿苋中富含ω-3脂肪酸、山奈酚、木樨草素、槲皮素、芹菜素等成分,能显著改善地塞米松诱导的高脂血症,包括降低血清总TC、TG、脂肪酸、LDL-C,升高HDL-C,抑制肝脏损伤。芹菜素诱导AMPK激活使PPARγ、SCD-1等与脂肪形成相关的基因表达降低,从而抑制脂肪形成。芹菜素不仅降低血清TC、TG、LDL-C,升高HDL-C,调节胆固醇代谢,从而发挥抗高脂血症的作用;也能抑制H2O2诱导的血管内皮细胞损伤,保护血管。壳聚糖(Chitosan)减轻高脂饮食诱导的大鼠体重、肝脏和心脏指数、脂肪/体重比,维持肝脏和血清SOD、ALT、AST活性,降低血清TC、TG、LDL-C水平,增加PPARα和肝脂肪酶(HL)表达,从而改善肝脏脂质的代谢,保护肝脏免受氧化损伤,可用于高脂血症治疗。网络药理学研究(图1)明确了所述用于高脂血和脂肪肝的药膳食疗产品组合物主治病症的相关靶点、有效成分、作用靶点,明确了主治病症-靶点-药效成分作用关系网络,明确了参与作用的生理/病理通路过程,同时,配方的成分-靶点-药理作用机制网络研究结果与主治病症衔接一致,符合现代精准医学原则。同时本品成本低,符合产业化生产需要。
优选地,所述用于高脂血和脂肪肝的药膳食疗产品组合物由以下重量份的原料制备而成:沙棘叶8~10份,辣木叶5~7份,菊苣8~10份,余甘子8~10份,马齿苋5~7份,决明子8~10份,野葛根8~10份,紫苏子8~10份,火麻仁8~10份,昆布5~7份,荷叶5~7份,壳寡糖0.4~0.6份,低聚木糖0.8~1.2份。更具体地,所述用于高脂血和脂肪肝的药膳食疗产品组合物由以下重量份的原料制备而成:沙棘叶9份,辣木叶6份,菊苣9份,余甘子9份,马齿苋6份,决明子9份,野葛根9份,紫苏子9份,火麻仁6份,昆布6份,荷叶6份,壳寡糖0.5份,低聚木糖1份。该处方全部采用食品级原料,安全有效,生产成本底,预防效果可靠。如图1所示,本品中很多成分可以有效的防治高血脂和缓解其引起的相关症状。是一款主成分清晰,靶点明确的精准药膳产品。由于网络药理学关系图1空间布局限制,用英文名称或缩写代替,具体中英文对应如表1所示。
表1
部分组分具体作用如表2所示:
表2
本发明实施例还提供上述用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法,其包括如下步骤:
按照上述用于高脂血和脂肪肝的药膳食疗产品组合物的重量份称取原料,将沙棘叶,辣木叶,菊苣,余甘子,马齿苋,决明子,野葛根,紫苏子,火麻仁,昆布和荷叶混合,加8~15倍质量份的水浸泡15~60分钟,加热回流提取0.5~2小时,80~200目过滤,得第一提取液;
向药渣中加8~15倍质量份的水回流提取0.5~2小时,80~200目过滤,得第二提取液;
将第一提取液和第二提取液混合,浓缩,加入壳寡糖和低聚木糖,获得所述用于高脂血和脂肪肝的药膳食疗产品组合物。
优选地,按照上述用于高脂血和脂肪肝的药膳食疗产品组合物的重量份称取原料,将决明子、火麻仁破碎,用纱布袋封装,再与沙棘叶,辣木叶,菊苣,余甘子,马齿苋,野葛根,紫苏子,昆布,荷叶混合,加8~15倍质量份的水浸泡20~40分钟,加热回流提取0.5~2小时,100~200目过滤,得第一提取液;
向药渣中加8~15倍质量份的水,加热回流提取0.5~2小时,100~200目过滤,得第二提取液。
更具体地,所述用于高脂血和脂肪肝的药膳食疗产品组合物,滤液减压浓缩至密度约为1.08,得浓缩液备用;浓缩液加入麦芽糊精,搅拌均匀,喷雾干燥(喷嘴进风温度设为150度,出风口温度80度),即得提取物粉末,备用。
取上述喷干粉加入壳寡糖和低聚木糖,混合均匀;分装,10g/袋,即得固体饮料。
或者,以上述喷雾干燥的粉末加入壳寡糖和低聚木糖,进行制粒,干燥,分装、10g/袋,制备成颗粒剂。
采用喷干粉,加入壳寡糖和低聚木糖等适宜的食品原料,进行制粒,干燥,压片;做成适宜的片剂形式即可。
产品的最终形式可以是多种,包括粉剂、颗粒、片剂、蜜丸、膏滋、口服液、糖浆剂等。制备工艺中,干燥方式可以是喷雾干燥、真空干燥、冷冻干燥等;制粒方法可以是干法制粒、湿法制粒、一步制粒等。
采用药学、食品、保健品等相关法规可以接受的方法,均可以对上述用于高脂血和脂肪肝的药膳食疗产品组合物进行提取、浓缩、干燥或粉碎,进一步加工为产品,保留复方的有效成分,制成适宜的给药形式(包括颗粒剂、粉剂、口服液、片剂等剂型)或者食品形式如压片糖果、餐粉、固体饮料等形式,满足市场对相关产品的需求,均属于本发明保护的范围。
以下通过具体配方和制备工艺的实施例来说明上述用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法。
实施例1:
称取沙棘叶9kg,辣木叶6kg,菊苣9kg,余甘子9kg,马齿苋6kg,野葛根9kg,紫苏子9kg,昆布6kg和荷叶6kg混合,将决明子9kg和火麻仁6kg破碎装袋,与上述组分混合,加水15倍浸泡30分钟,加热回流提取1小时,200目过滤,药渣加12倍水回流提取1小时;合并两次提取液,减压浓缩密度约为1.08,加入麦芽糊精适量,喷雾干燥,即得提取物;加入0.5kg寡聚糖和1kg低聚木糖,混合均匀,上粉末包装机,分装,制成固体饮料,10g/袋。
实施例2:
选择100位血脂高患者作为保健品每日服用上述用于高脂血和脂肪肝的药膳食疗产品组合物制备的固体饮料,每天2~3次;每次取本品一袋,加入100~200毫升热水冲调搅至溶解后,食用。连服两周,有80%以上患者的血脂有不同程度的降低。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种用于高脂血和脂肪肝的药膳食疗产品组合物,其特征在于,所述药膳食疗组合物由以下重量份的原料制备而成:
沙棘叶1~15份,
辣木叶1~20份,
菊苣1~15份,
余甘子1~20份,
马齿苋1~20份,
决明子1~20份,
野葛根1~15份,
紫苏子1~15份,
火麻仁1~20份,
昆布1~16份,
荷叶1~15份,
壳寡糖0.1~3份,
低聚木糖0.5~5份。
2.如权利要求1所述的用于高脂血和脂肪肝的药膳食疗产品组合物,其特征在于,所述药膳食疗组合物由以下重量份的原料制备而成:
沙棘叶8~10份,
辣木叶5~7份,
菊苣8~10份,
余甘子8~10份,
马齿苋5~7份,
决明子8~10份,
野葛根8~10份,
紫苏子8~10份,
火麻仁8~10份,
昆布5~7份,
荷叶5~7份,
壳寡糖0.4~0.6份,
低聚木糖0.8~1.2份。
3.如权利要求2所述的用于高脂血和脂肪肝的药膳食疗产品组合物,其特征在于,所述药膳食疗组合物由以下重量份的原料制备而成:
沙棘叶9份,
辣木叶6份,
菊苣9份,
余甘子9份,
马齿苋6份,
决明子9份,
野葛根9份,
紫苏子9份,
火麻仁6份,
昆布6份,
荷叶6份,
壳寡糖0.5份,
低聚木糖1份。
4.一种用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法,其特征在于,包括如下步骤:
按照权利要求1~3任一所述的用于高脂血和脂肪肝的药膳食疗产品组合物的重量份称取原料,将沙棘叶,辣木叶,菊苣,余甘子,马齿苋,决明子,野葛根,紫苏子,火麻仁,昆布和荷叶混合,加8~15倍质量份的水浸泡15~60分钟,加热回流提取0.5~2小时,80~200目过滤,得第一提取液;
向药渣中加8~15倍质量份的水回流提取0.5~2小时,80~200目过滤,得第二提取液;
将第一提取液和第二提取液混合,浓缩,加入壳寡糖和低聚木糖,获得所述用于高脂血和脂肪肝的药膳食疗产品组合物。
5.如权利要求4所述的用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法,其特征在于,将决明子、火麻仁破碎,用纱布袋封装,再与沙棘叶,辣木叶,菊苣,余甘子,马齿苋,野葛根,紫苏子,昆布,荷叶混合。
6.如权利要求4所述的用于高脂血和脂肪肝的药膳食疗产品组合物的制备方法,其特征在于,向药渣中加10~15倍质量份的水。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/139698 WO2022021779A1 (zh) | 2020-07-28 | 2020-12-25 | 用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020107383908 | 2020-07-28 | ||
CN202010738390 | 2020-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112353850A true CN112353850A (zh) | 2021-02-12 |
Family
ID=74533259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011328982.9A Pending CN112353850A (zh) | 2020-07-28 | 2020-11-24 | 用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112353850A (zh) |
WO (1) | WO2022021779A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113349376A (zh) * | 2021-05-28 | 2021-09-07 | 华东理工大学 | 一种寡糖基降脂护肝特殊医学用途配方食品及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116747289B (zh) * | 2023-07-31 | 2024-03-29 | 广东润科生物科技有限公司 | 一种清脂组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106387904A (zh) * | 2016-09-30 | 2017-02-15 | 楚雄州百草岭药业发展有限公司 | 一种组合物及其制备方法、制剂与应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1131060C (zh) * | 2001-08-17 | 2003-12-17 | 南京医科大学 | 治疗脂肪肝的中药复方制剂 |
CN101455739A (zh) * | 2007-12-14 | 2009-06-17 | 北京琥珀光华医药科技开发有限公司 | 一种治疗高脂血症的纯中药制剂 |
CN104225302B (zh) * | 2014-08-29 | 2017-06-27 | 苏州雷允上健康养生有限公司 | 一种具有降压降脂降糖作用的组合物及其制备方法和应用 |
CN104208275B (zh) * | 2014-08-29 | 2017-08-01 | 苏州雷允上健康养生有限公司 | 一种具有改善脂肪肝、降低体重作用的组合物及其制备方法和应用 |
CN105708762B (zh) * | 2016-03-21 | 2019-04-19 | 哈尔滨康鸿生物科技有限公司 | 一种决明子降脂牙膏 |
JP6145552B1 (ja) * | 2016-11-18 | 2017-06-14 | 正則 那須 | 脂肪肝治療用組成物 |
CN107296949A (zh) * | 2017-07-13 | 2017-10-27 | 山东仁迪生物工程集团有限公司 | 药食同源复合制剂及其制备方法和应用 |
-
2020
- 2020-11-24 CN CN202011328982.9A patent/CN112353850A/zh active Pending
- 2020-12-25 WO PCT/CN2020/139698 patent/WO2022021779A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106387904A (zh) * | 2016-09-30 | 2017-02-15 | 楚雄州百草岭药业发展有限公司 | 一种组合物及其制备方法、制剂与应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113349376A (zh) * | 2021-05-28 | 2021-09-07 | 华东理工大学 | 一种寡糖基降脂护肝特殊医学用途配方食品及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2022021779A1 (zh) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | Polygonati Rhizoma with the homology of medicine and food: A review of ethnopharmacology, botany, phytochemistry, pharmacology and applications | |
CN112353850A (zh) | 用于高脂血和脂肪肝的药膳食疗产品组合物及其制备方法 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN112385841A (zh) | 一种用于2型糖尿病的药膳食疗组合物及其制备方法 | |
KR101313284B1 (ko) | 총백 추출물을 유효성분으로 함유하는 지질 관련 심혈관 질환 또는 비만의 예방 및 치료용 조성물 | |
CN113730464A (zh) | 香连丸及其提取物、药物组合物与香连丸产物的新用途 | |
US10413579B2 (en) | Pharmaceutical composition for preventing or treating asthma comprising Pistacia weinmannifolia J. Poiss. ex Franch extract or fraction thereof | |
AU2021106305A4 (en) | Medicinal diet product composition for hyperlipemia and fatty liver and preparation method thereof | |
CN111253459B (zh) | 一种三七皂苷炮制品及其制备方法和应用 | |
KR101336068B1 (ko) | 한약재의 추출물과 분획물을 포함하는 항당뇨 조성물 | |
KR101181347B1 (ko) | 백선피 추출물을 유효성분으로 포함하는 지질 관련 심혈관 질환 또는 비만의 예방 및 치료용 조성물 | |
Marchyshyn et al. | Study of hypoglycemic activity of extract of yacon (Polymnia sonchifolia Poepp. & Endl.) root tubers | |
WO2005072757A1 (en) | Imperatae rhizoma extract for treatment and prevention of obesity | |
CN112472779A (zh) | 一种用于冠心病的药膳食疗产品组合物及其制备方法 | |
CN111870626B (zh) | 一种具有降血脂作用的药物组合物及其制备方法和应用 | |
KR101688126B1 (ko) | 고지혈증 또는 비만의 예방 또는 치료용 약제학적 조성물 및 이의 제조 방법 | |
CN113694105B (zh) | 一种具有降血脂功能的组合物及其应用 | |
KR101241338B1 (ko) | 편축 추출물을 유효성분으로 함유하는 지질 관련 심혈관 질환 또는 비만의 예방 및 치료용 조성물 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
CN109200092A (zh) | 一组由果糖和丹参组成的改善能量代谢的保健食品及药品 | |
CN102793798A (zh) | 一种用于糖尿病性冠心病辅助治疗的药物组合物 | |
KR20050102017A (ko) | 식초 가공 인삼제제를 이용한 제2형 당뇨병과대사증후군의 예방 및 치료용 조성물 | |
KR102501310B1 (ko) | 항비만용 조성물 | |
WO2023128540A1 (ko) | 갯까치수영 추출물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
CN101450096A (zh) | 一种具有降血糖功能的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |